Osmotica Pharmaceuticals plc - FORM 10-K - EX-23.1 - March 18, 2020

Attached files

file filename
EX-32.2 - EX-32.2 - Osmotica Pharmaceuticals plcosmt-20191231ex322b98716.htm
EX-32.1 - EX-32.1 - Osmotica Pharmaceuticals plcosmt-20191231ex32174ac80.htm
EX-31.2 - EX-31.2 - Osmotica Pharmaceuticals plcosmt-20191231ex312cfbe17.htm
EX-31.1 - EX-31.1 - Osmotica Pharmaceuticals plcosmt-20191231ex31145d621.htm
EX-23.2 - EX-23.2 - Osmotica Pharmaceuticals plcosmt-20191231ex2320e0427.htm
EX-21.1 - EX-21.1 - Osmotica Pharmaceuticals plcosmt-20191231ex2110163ba.htm
EX-10.37 - EX-10.37 - Osmotica Pharmaceuticals plcosmt-20191231ex10379f85d.htm
EX-10.36 - EX-10.36 - Osmotica Pharmaceuticals plcosmt-20191231ex103680d9c.htm
EX-10.35 - EX-10.35 - Osmotica Pharmaceuticals plcosmt-20191231ex10351998f.htm
EX-4.3 - EX-4.3 - Osmotica Pharmaceuticals plcosmt-20191231ex439b86345.htm
10-K - 10-K - Osmotica Pharmaceuticals plcosmt-20191231x10k.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the following Registration Statements:

 

(1)

Registration Statement (Form S-3 No. 333-236193), and

(2)

Registration Statement (Form S-8 No. 333-228045;

 

of our report dated March 19, 2020, with respect to the consolidated financial statements of Osmotica Pharmaceuticals plc included in this Annual Report (Form 10-K) of Osmotica Pharmaceuticals plc for the year ended December 31, 2019.

 

/s/Ernst & Young LLP

Iselin, New Jersey

March 19, 2020

 

Osmotica Pharmaceuticals plc Reports